Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric maltol - Shield Therapeutics

Next Previous
Drug Profile

Ferric maltol - Shield Therapeutics

Alternative Names: ACCRUFeR; Accrufer; FeRACCRU; Feraccru; Iron (III) maltol; ST-10; ST10-021

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Cambridge; University of London
  • Developer KYE Pharmaceuticals; Norgine; Shield Therapeutics
  • Class Antianaemics; Ferric compounds; Pyrones; Small molecules
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 09 Feb 2026 US FDA grants an additional 3 years of Data Exclusivity for Ferric maltol
  • 30 Jan 2026 Beijing Aosaikang Pharmaceutical plans to files marketing authorization application with the NMPA in China for Iron deficiency anemia (In adolescents, In adults, In children) in first quarter of 2026
  • 08 Jan 2026 Launched for Iron deficiency anaemia in Poland, Ireland, Finland, Netherlands, Sweden, Denmark (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top